MGC Pharmaceuticals
Biopharmaceutical drug discovery targeting immunology and neurology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $500k | Private Placement VC |
| Total Funding | 000k | ||
| AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 121 % | 210 % | 46 % | 57 % | (27 %) | (74 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2266 %) | (1288 %) | (443 %) | (405 %) | (304 %) | (458 %) | (1904 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2778 %) | (352 %) | (952 %) | (471 %) | (361 %) | (615 %) | (1967 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | 59 % | - |
Source: Company filings or news article
Related Content
Argent BioPharma Ltd, formerly known as MGC Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs in immunology and neurology. Founded in 2014 and dual-listed on the Australian and London Stock Exchanges, the company underwent a significant restructuring and rebranding in April 2024 to become Argent BioPharma, a move supported by a substantial capital injection.
The company was co-founded by Roby Reuven Zomer, who serves as the Managing Director and CEO. Argent BioPharma leverages a scientific approach called Polypharmacology, which involves creating therapies that act on multiple molecular targets simultaneously to tackle complex diseases. It also utilizes nanotechnology to enhance drug delivery and efficacy. The company's business model generates early-stage revenue through Investigational Medicinal Product (IMP) sales via early access schemes in the UK, USA, and Europe, which also provides real-world data to support clinical trials.
Argent BioPharma's product pipeline includes several key candidates. CimetrA®, for acute lung injury and ARDS, is currently in Phase 2B studies. CannEpil®, a treatment for refractory epilepsy and cerebral palsy, is entering Phase 2B trials under FDA guidelines. CogniCann®, designed to improve quality of life for dementia and Alzheimer's patients, has completed Phase 2A studies. The company operates its own European research hub and EU GMP-certified manufacturing facilities, giving it control over the entire drug development lifecycle from concept to commercialization.
Keywords: biopharmaceutical, drug discovery, immunology, neurology, polypharmacology, nanotechnology, clinical trials, central nervous system, orphan drugs, CimetrA, CannEpil, CogniCann, refractory epilepsy, acute lung injury, ARDS, dementia, Alzheimer's, phytocannabinoid, GMP manufacturing, early access schemes
